National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.

Inhaled Insulin (Exubera) summary